** Shares of drug developer Cassava Sciences SAVA.O down 85.42% premarket to $3.86, its experimental Alzheimer's disease drug, simufilam, did not meet the main or secondary goals in a late-stage study.
** As a result, Cassava will discontinue a second late-stage study, as well as its open-label study of the drug
** Cassava's shares were halted in premarket hours ahead of the announcement
** Up to the previous session's close, shares were up 17.6% YTD
(Repoting by Joao Manuel Mauricio)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.